Eduardo Bravo Founder of Citryll Backed bySeventure PartnersIsabelle de Cremoux LinkedIn SourcesCitryll Raises EUR 85 Million Series B To Advance Novel NET-Targeting Therapy For Immune-Mediated Inflammatory Disorders — 2024-12 Browse all founders · Browse investors
